CCM
APLT

Coldstream Capital Management’s Applied Therapeutics APLT Stock Holding History

Coldstream Capital Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,054
Closed -$516 – 1243
2025
Q1 		$516 Buy
+1,054
New +$621 ﹤0.01% 3346

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Coldstream Capital Management's APLT Position: Q2 2025 in Review

Coldstream Capital Management sold out of Applied Therapeutics (APLT) in Q2 2025, closing a stake of 1,054 shares — an estimated $516 sold.

Coldstream Capital Management first reported a position in APLT in Q1 2025 and held it in 1 quarter. The position peaked at $516 in Q1 2025. 75 funds tracked by Wall St. Rank hold APLT as of Q2 2025.

  • Coldstream Capital Management reported no remaining Applied Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 1,054 Applied Therapeutics shares in Q2 2025, an estimated $516.
  • Coldstream Capital Management first reported a position in Applied Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Applied Therapeutics position peaked at $516 in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.